W
WAVEMAN · COMPANY
ANTX · An2 Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

ANTX

AN2 Therapeutics, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001880438
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-$228.6K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
43
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$228.6K over 180 days
-$227.4K over 90 days
more than 51% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
43 funds added or opened last quarter
below 58% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
6.3% of shares outstanding short · 14.8 days to cover · settled 2026-07-31
more than 61% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$228.6K across 3 people in 180 days.
43 funds added or opened positions in the latest 13F quarter, of 67 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +412.2%
+412.2%12M
-10%+142%+294%+446%2025-092025-102025-122026-032026-052026-072026-09 2026-08-17 · Readnour Robin Shane sold $112.4K2026-08-17 · Readnour Robin Shane sold $100.3K2026-07-08 · Eizen Joshua M sold $24.8K2026-01-05 · Eizen Joshua M sold $17.9K2026-09-01 · FitzPatrick Margaret M bought $11.6K2026-01-06 · Eizen Joshua M sold $7.0K2026-01-06 · Chanda Sanjay sold $6.0K2026-01-06 · Day Lucy sold $5.6K2026-01-05 · Prior Stephen David sold $3.6K2026-01-05 · Day Lucy sold $3.3K2026-01-05 · Chanda Sanjay sold $3.3K2025-11-04 · Eizen Joshua M sold $3.2K2026-01-06 · Prior Stephen David sold $2.9K2026-09-01 · Williams Sarah Joanne sold $1.5K2026-05-29 · Williams Sarah Joanne sold $1.2K2025-11-04 · Prior Stephen David sold $8722026-03-03 · Williams Sarah Joanne sold $3472026-08-17 · Readnour Robin Shane filed to sell $6.1M
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $228.6K sold by insiders over 180 days, 43 funds added last quarter, $6.1M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, AN2 Therapeutics, Inc. insiders sold a net $228.6K of stock across 132 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
FitzPatrick Margaret M
Director
BUY
2026-09-01
2,098.0
$11.6K
Williams Sarah Joanne
Principal Accounting Officer
SELL
2026-09-01
272.0
$1.5K
Readnour Robin Shane
Director
SELL
2026-08-17
16,696.0
$100.3K
Readnour Robin Shane
Director
SELL
2026-08-17
18,706.0
$112.4K
Eizen Joshua M
See Remarks
SELL
2026-07-08
5,945.0
$24.8K
132 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 127 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Vivo Capital, LLC
3,153,640.0 sh
$15.3M
Commodore Capital LP
2,933,680.0 sh
$14.2M
MILLENNIUM MANAGEMENT LLC
2,318,692.0 sh
$11.2M
BlackRock, Inc.
1,665,494.0 sh
$8.1M
Spruce Street Capital LP
1,661,073.0 sh
$8.0M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Readnour Robin Shane
FILED 2026-08-17
$6.1M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Ultra-Small Company Market Fund
$201.8K POSITION · AS OF 2026-03-31
0.2%
iShares Micro-Cap ETF
$181.8K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$13.4K POSITION · AS OF 2026-03-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$862.2K POSITION · AS OF 2026-03-31
0.0%
Dimensional U.S. Small Cap ETF
$120.2K POSITION · AS OF 2026-04-30
0.0%
U.S. MICRO CAP PORTFOLIO
$38.7K POSITION · AS OF 2026-04-30
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 5 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
3
Phase 1
0 ACTIVE
1
Not applicable
0 ACTIVE
1
Multi-phase
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Government contracts
USASpending.gov · total award ceilings over the contract's life, including awards won through subsidiaries — not annual revenue
Department Of Health And Human Services
DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESI · 2022-09-20
$9.2M
FEDERAL AWARDS ≥ $25M IN THE LAST 90 DAYS · MATCHED VIA SAM.GOV PARENT REGISTRY
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-38.1M$-56.8M$-69.6M$-42.3M
NET INCOME$-35.2M$-51.3M$-64.7M$-41.0M
EPS (DILUTED)-1.16-1.72-2.74-2.79
OPERATING CASH FLOW$-29.8M$-49.3M$-53.3M$-33.5M
CASH$19.9M$21.4M$15.6M$27.2M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →